AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.

Discover More

Our Mission &
Sole Focus

To discover and develop innovative therapeutics that preserve and restore brain function for patients at risk for neurodegeneration, benefiting the lives of patients, their families, and society as a whole.

Nearly every minute, someone in America transitions from normal aging when occasional senior moments of memory loss become an everyday part of life. This condition is called mild cognitive impairment due to Alzheimer’s disease (MCI due to AD), the earliest symptomatic stage characterized by memory loss. For most people, their memory will worsen and within a few years, their condition will transition to Alzheimer’s dementia. Unfortunately, today there is no treatment for patients experiencing MCI due to AD.

stages of brain neurodegeneration with hippocampus overactivity

Decades of research show the the best prospect to prevent and delay progression to Alzheimer’s dementia is to intervene as early as possible, at the stage of MCI due to AD. Currently, patients with MCI due to AD have no treatment for their symptoms or therapy to prevent Alzheimer’s dementia. The goal of AgeneBio’s lead development program is to provide a solution to this unmet medical need.

Learn More About MCI due to AD

Our Science

Our science and intellectual property are based on decades of unparalleled research at Johns Hopkins and leading research centers worldwide demonstrating that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled.

Our Pipeline

Our pipeline includes multiple candidates to treat patients with neurological and psychiatric disease.

for MCI due to AD

Our lead candidate, AGB101, is in Phase 3 clinical testing. AGB101 is being studied in patients with MCI due to AD to see if it improves the brain network imbalance that leads to memory loss and brain atrophy. It is also being evaluated to see if it slows the progression to and delays the onset of Alzheimer’s dementia. Currently there are no treatments that have shown these benefits. Learn more here:


Discovery Program

Our second development program is a novel GABAA a5 late-stage discovery program being investigated for a spectrum of conditions including MCI due to AD, autism and schizophrenia.

These investigational compounds are not approved by the FDA. The safety and efficacy have not been established.